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Abstract
Aims/hypothesis Using the Echantillon Généraliste de Bén-
éficiaires: random 1/97 permanent sample of the French
national healthcare insurance system database (EGB), we
investigated whether, as previously suspected, the risk of
cancer in insulin glargine (A21Gly,B31Arg,B32Arg human
insulin) users is higher than in human insulin users. The
investigation period was from 1 January 2003 to 30 June
2010.
Methods We used Cox proportional hazards time-dependent
models that were stratified on propensity score quartiles for
use of insulin glargine vs human insulin, and adjusted for
insulin, biguanide and sulfonylurea possession rates to assess
the risk of cancer or death in all or incident exclusive or
predominant (≥80% use time) users of insulin glargine com-
pared with equivalent human insulin users.
Results Only type 2 diabetic patients were studied. Exposure
rates varied from 2,273 and 614 patient-years for incident
exclusive users of insulin glargine or human insulin, respec-
tively, to 3125 and 2341 patient-years for all patients predom-
inantly using insulin glargine or human insulin, respectively.
All-type cancer HRs with insulin glargine vs human insulin
ranged from 0.59 (95% CI 0.28, 1.25) in incident exclusive
users to 0.58 (95% CI 0.34, 1.01) in all predominant users.
Cancer risk increased with exposure to insulin or sulfonylur-
eas in these patients. Adjusted HRs for death or cancer asso-
ciated with insulin glargine compared with human insulin
ranged from 0.58 (95% CI 0.32, 1.06) to 0.56 (95% CI 0.36,
0.87).
Conclusions/interpretation There was no excess risk of can-
cer in type 2 diabetic patients on insulin glargine alone
compared with those on human insulin alone. The overall
risk of death or cancer in patients on insulin glargine was
abouthalfthatofpatientsonhumaninsulin,therebyexcluding
a competitive risk bias.
Keywords Cancer.Cohortstudy.Databasestudy.Human
insulin.Insulinglargine.Sulfonylureas.Type2diabetes
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Introduction
The question of a possible increased risk of cancer, especially
breast cancer, in users of the insulin analogue, glargine
(A21Gly, B31Arg, B32Arg human insulin), was raised fol-
lowing the publication of experimental data showing a higher
affinity of insulin glargine for IGF1 receptors and signalling
pathways, and a pro-angiogenic effect [1–5], with possible
promoting and anti-apoptotic effects on human breast cancer
cells [6]. Epidemiological studies also found an increased
dose-dependent relative risk of cancer in exclusive users of
insulin glargine [7, 8]. This excess risk of cancer was not
confirmed in meta-analyses of short-term clinical trials [9]o r
in a long-term open trial [10] or in other epidemiological
studies [11, 12]. A re-analysis of the database that provided
one of the initial signals confirmed the initial signal, but was
unabletoreproduce itinlateryears[13].There hasbeenmuch
discussion of the real meaning of these findings [14, 15], the
relative role of insulin itself or its analogues in the increased
risk of cancer [16–18], the role of diabetes and hyperglycae-
mia as such [19, 20], or even of the reality of an increased risk
of cancer in insulin users [21–23].
Because of these uncertainties, and notwithstanding an
on-going risk management programme [24], we explored
the Echantillon Généraliste de Bénéficiaires: random 1/97
permanent sample of the French national healthcare insurance
system database (EGB) [25] to test for a possible association
between the dispensing of insulin glargine and the occurrence
of cancer. Since increased mortality rates might hide an in-
creased risk of cancer, the combined outcome of death or
cancer was also studied. We also tested a possible effect of
increasing exposure to insulin, sulfonylureas and metformin
on the event rates for cancer.
Methods
Data source This was a cohort study in the EGB, which is a
permanent random sample of the French national healthcare
insurance system database that covers approximately 90%
of the French population [25].
The EGB includes basic demographic data and has pro-
spectively collected all reimbursed medical expenses since
2002. In the mandatory French national healthcare system,
the vast majority of prescribed medications for any indication
or any duration are reimbursed with variable co-payment
schemes, usually 15%, 35%, 65% or 100% coverage by the
national healthcare insurance. The EGB contains data on all
reimbursed medicines at whatever co-payment level, includ-
ing dates of prescription, dispensing and preparation, and
quantities dispensed. This information is captured automati-
callyat the time of drug dispensing by the pharmacy or,
when a medical or other procedure is done, at the end of a
consultation.
In the French healthcare system, 31 major chronic dis-
eases, including diabetes and cancer, have been designated
by the healthcare insurance as ‘Affection de Longue Durée’
(ALD), i.e. chronic disease, and result in full insurance
cover of all medical and pharmaceutical expenses related
to the disease. Registration for one of these chronic diseases
is proposed by the treating physician and confirmed by the
healthcare insurance system physicians, based on the
clinical information provided by the treating physician and,
if necessary, by physical examination. The information
recorded includes the chronic disease code, the associated
International Classification of Diseases (ICD)-10 codes
(www.who.int/classifications/icd/en/) and the date offirst reg-
istration for the ALD. There is no diagnostic information on
non-ALD acute disorders, but all medical interventions and
prescribed medicines are included in the database, whatever
the indication, allowing for some proxy assessment of such
conditions. Most conditions that are included in the Charlson
index (e.g. myocardial infarction, stroke) are either directly
included as diagnostic codes or can be derived from the
prescriptions. The EGB also includes the date of death, but
not its cause.
Study populations The study population was all adult
patients (≥18 years) who had at least two prescriptions for
insulin dispensed between 1 January 2003 and 31 December
2009 and were without cancer diagnosis at the time of
dispensing the first insulin prescription or had not died in
the month after dispensing of the first insulin prescription,
and who had not had more than 1 year without claims in the
database after dispensing of the first insulin prescription.
Exclusive users were those who had received only insulin
glargine or the same human insulin (mostly NPH-type basal
insulin) between the first and last dispensing of prescriptions
for insulin. Predominant users were those who had at least
12 prescriptions for insulin dispensed, with at least 80% of
the exposure time on the same insulin; this group also
includes exclusive users. Incident users were patients for
whom at least 6 months of data prior to the first dispensing
of a prescription for any insulin were available. Based on the
above, four populations were defined: (1) incident exclusive
users; (2) incident predominant users; (3) all exclusive
users; and (4) all predominant users. Numbers of patients
for these groups are given in Fig. 1. Each population was
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populations, with the most restricted being incident exclu-
sive and the largest being all predominant. The primary
hypothesis was tested in the most restricted population, i.e.
in incident exclusive users. The other populations were used
for sensitivity analyses.
Study and exposure periods The study period was from 1
January 2003 to 30 June 2010. The index date was the time
of dispensing the first insulin prescription identified in the
database. The exposure period was defined as the time from
first dispensing of insulin to 28 days after the date of last
dispensing, thus taking into account the usual duration of a
dispensing for chronic treatment in France. Follow-up was
censured to 30 June 2010. There was at least 6 months of
follow-up for all patients included.
Outcomes Outcomes of interest were the first occurrence of a
registration for cancer or occurrence of death during the
follow-up. The type of cancer was recorded, but not the cause
of death.
The pre-specified study hypothesis was that there would
be an excess of cancer diagnoses in the population of incident
exclusive users of insulin glargine compared with incident
exclusive users of human insulin. The other populations (all
users, predominant users) were used as sensitivity analyses,
progressively increasing the numbers of patients and events.
Increasing risk of cancer diagnoses with increasing ex-
posure to insulin or sulfonylureas [26, 27] and reduced risk
with biguanides [28] were secondary hypotheses.
Because death rates in this population are high and death
might be due to a concurrent risk, we also tested the HRs of
death or cancer, with the hypothesis that a higher death rate
might mask an imbalance in the risk of cancer.
Statistical analysis To estimate the probability of receiving
insulin glargine or human insulin, a propensity score was
constructed using logistic regression with the following
baseline characteristics: sex, age at first dispensing of insulin,
incident user or not, type 1 or 2 diabetes, date of long-term
disease inscription for diabetes, four categories of chronic
diseases with 100% coverage (severe hypertension, cardio-
vascular diseases, psychiatric disorders, other diseases) and
the number of systemic drug dispensing according to the first
level of the Anatomical Therapeutic Chemical classification
of medicines (WHO) (ATC) for 6 months before the first
dispensing of insulin for incident users and for the first
6 months in the database for the other patients. With regard
to drug dispensing, some specific drug classes were included
separately (e.g. oral glucose-lowering drugs and lipid-
lowering agents, to distinguish them from other cardiovascu-
lar drugs, or vaccines, to distinguish them from other anti-
infective drugs).
The treatment or medication possession rate (PR) was
defined by the ratio of the number of treatments dispensed
during the insulin exposure period divided by the number of
28 day periods during the follow-up period. This was com-
puted for insulin, biguanide, sulfonylureas and other oral
glucose-lowering treatments, as an indicator of the intensity
of drug exposure.
Patients with ≥1 insulin prescription between 1 January 2003 and 31 December 2009
N=8,485  
￿ <18 years old  n=234 (2.8%)
￿ <2 insulin prescriptions before 30 June 2010  n=923 (10.9%)
￿ Cancer diagnosis before dispensing of first insulin prescription n=594 (7.0%)
￿ Death in the month after dispensing of  first insulin prescription n=6     (0.1%)
￿ ≥1 year without claims after dispensing of insulin prescription n=79   (1.0%)
Source population 
classified according 
to first insulin prescription
n=6,649
￿ Insulin glargine (IG)  n=1,536 (23.1%)
￿ Human insulin (HI)  n=2,510 (37.7%)
￿ Other insulin analogue n=1,234 (18.6%)
￿ Insulin association  n=1,369 (20.6%)
All predominanta users
(type 1 and 2 diabetic)
IG  n=1,174
HI  n= 943
All exclusivea users
(type 1 and 2 diabetic)
IG  n=1,011
HI  n=804
All predominanta users
(type 2 diabetic)
IG  n=1,140
HI  n=703
All exclusivea users
(type 2 diabetic)
IG  n=979
HI  n=586
Incident predominanta
users (type 2 diabetic)
IG  n=1,049
HI  n=318
Incident exclusive users
(type 2 diabetic)
IG  n=927
HI  n=272
Fig. 1 Patient group selection.
aExclusive users were patients
who used only the same type
of insulin throughout the study
period; predominant users
were users with at least 80%
prescriptions for the insulin
of interest. Only exclusive or
predominant insulin glargine
and human insulin users were
included in the study
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hazards Cox models. For each outcome (cancer, cancer or
death), the HR and its 95% CI associated with exposure to
insulin glargine compared with human insulin was estimated
in the four populations defined above. Propensity scores
were tested separately as an adjustment covariate and a
quartile stratifying covariate. Other covariates used for
adjustment were the insulin PR, the biguanide PR, the
sulfonylurea PR and the PR for other oral glucose-
lowering treatments. The proportionality of risks was ver-
ified. In addition, crude Kaplan–Meier survival curves were
drawn.
Results
Patient group selection and the analysis cohorts are shown in
Fig. 1. Of 8,485 patients with a first dispensing of insulin,
6,649 were initially included. Because in incident type 1
diabetic patients there was no case of cancer in those exposed
to insulin glargine and only one in those exposed to human
insulin, further analyses were restricted to type 2 diabetic
patients. Of these type 2 diabetic patients, 1,199 were incident
exclusive users (most restrictive population) and 1,843 were
all predominant users (largest group). Baseline insulin glar-
gine and human insulin patient characteristics were very sim-
ilarfromthemostrestrictivetothemoreextensivepopulations
(Tables 1 and 2), even though the population size, which did
not change much with insulin glargine (from 927 to 1,140
patients), almost tripled with human insulin (from 272 to 703
subjects). Patients on insulin glargine or human insulin had
the same age within a year or two. More men were on insulin
glargine (50%) than on human insulin (40%). Patients on
insulin glargine had more concomitant diseases and medica-
tions (Table 1). More than 70% of patients on human insulin
were exposed only to NPH insulin, with 30% exposed to
premix insulins combining intermediate and fast-acting
insulins.
Exposures varied from 2,273 to 3,125 patient-years for
insulin glargine and from 614 to 2,340 patient-years for
human insulin. Cancer was reported in 18.0 (95% CI 12.5,
23.6) and 22.8 (95% CI 10.9, 34.7) per 1,000 patient-years
in exclusive users of insulin glargine and human insulin,
respectively (Table 2), and in 14.7 (95% CI 10.5, 19.0) and
24.3 (95% CI 18.0, 30.7) per 1,000 patient-years in all
predominant insulin glargine and human insulin patients.
The main study endpoint, the HR for diagnoses of cancer
with insulin glargine compared with human insulin in inci-
dent exclusive users, was 0.59 (95% CI 0.28, 1.25). This
value for all predominant users was 0.58 (95% CI 0.34,
1.01; Table 2). The results were the same, regardless of
whether the propensity score was used as a continuous
adjustment variable or as a stratifying variable. Kaplan–
Meier all-cause cancer-free crude survival curves were very
similar, parallel or superimposed (not shown).
There was no significant difference in the event rates for
the more common types of cancer. More specifically, in all
population groups there were numerically more cases and
higher event rates for breast cancers in users of human
insulin than in users of insulin glargine (Table 3).
For the secondary endpoints, the occurrence of cancer
diagnoses was associated with increasing insulin exposure
as assessed by the PR, ranging for insulin possession rate
(IPR) 80% to 100% vs 0% to 20% from 2.14 (95% CI 0.97,
4.72) in the incident exclusive population to 2.26 (95% CI
1.26, 4.06) in all predominant users (Table 2). Cancer diag-
noses were also associated with exposure to sulfonylureas
for all populations, ranging for PR 80% to 100% vs 0% to
20% from 2.30 (95% CI 1.17, 4.54) for incident exclusive
patients to 2.28 (95% CI 1.38, 3.76) for all predominant
patients (Table 2 ). Although exposure to biguanide was
generally associated with an HR below 1, this never reached
significance and did not show clear exposure-dependence
(Table 2).
Death or cancer was reported in 22.4 (95% CI 16.3, 28.6)
per thousand patient-years for incident exclusive users of
insulin glargine and in 45.6 (95% CI 28.7, 62.5) per thou-
sand patient-years for users of human insulin. The HR for
all-cause death or cancer with insulin glargine compared
with human insulin, stratified by the propensity score and
adjusted for drug possession ratios, varied from 0.58 (95%
CI 0.32, 1.06) in incident exclusive users to 0.56 (95% CI
0.36, 0.87) in all predominant patients. The hypothesis of a
concurrent risk of death masking the risk of cancer in insulin
glargine patients was thus not verified. Risk of cancer or
death was also increased in the higher stratum of the IPR
(80% to 100% vs 0% to 20%), ranging from adjusted HR
2.94 (95% CI 1.52, 5.68) in incident exclusive users to 2.82
(95% CI 1.75, 4.55) in all predominant users. A moderately
increased risk of cancer or death in the higher stratum of
sulfonylurea exposure was also found; it ranged from HR
1.62 (95% CI 0.89, 2.94) in exclusive incident users to 1.87
(95% CI 1.22, 2.87) in all predominant users.
Discussion
In this random sample of the national healthcare insurance
reimbursement database, we found that the dispensing of
insulin glargine alone was not associated with an increased
risk of subsequent cancer diagnoses compared with human
insulin alone. Our analysis used multivariate Cox analysis
stratified for propensity scores and exposure to glucose-
lowering drugs. The upper limit of the 95% CI of this HR
was lower than the HR reported in previous studies [7, 8],
allowing us to confidently rule out the possibility that
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representative sample of the French population.
We detected an association of increasing mean PR for
any insulin and for sulfonylureas with the risk of cancer,
adding weight to the hypothesis that increased risk of cancer
is associated with increased insulin exposure, whether exog-
enous or stimulated.
Various sensitivity analyses, including patients with at
least 80% of exposure time on the same insulin, or including
only incident (previously untreated with insulin for at least
6 months) or all patients treated with insulin, reached the
same conclusion with little variation in the point estimates
for the HRs. There was little difference between crude and
adjusted risk ratios.
The main hypothesis for this study was based on the
studies that appeared in 2009 in Diabetologia [7, 8, 11, 29]
and were the source of much controversy [30]. These studies
found that the incidence of cancer seemed greater in patients
dispensed only insulin glargine than in patients dispensed
only human insulin. They also found no overall difference
between different insulin types, but post-hoc analyses found
an increased risk of cancer, especially of the breast, in
Table 1 Baseline characteristics
of incident type 2 diabetic
patients exposed to insulin
glargine or human insulin
as indicated
aNumber of prescriptions for
insulin dispensed during the
6 months prior to index date
(incident patients) or during the
6 months after inclusion in the
database (non-incident patients)
for insulin dispensation;
classifications are by ATC
bProportion of prescriptions
for insulin dispensed during
exposure period to total number
of possible prescriptions
for insulin
Characteristic Exclusive incident users All predominant users
Insulin
glargine
Human
insulin
Insulin
glargine
Human
insulin
n 927 272 1,140 703
Male sex, n (%) 467 (50.4) 108 (39.7) 575 (50.4) 291 (41.4)
Age at first dispensing of insulin, mean (SD) 68.1 (13.3) 69.7 (15.2) 67.8 (13.2) 69.9 (13.6)
Long-term disease inscription for diabetes, n (%)
Before 1995 156 (16.8) 74 (27.2) 216 (18.9) 284 (40.4)
1995–1999 194 (20.9) 41 (15.1) 245 (21.5) 136 (19.3)
2000–2004 441 (47.6) 123 (45.2) 513 (45.0) 243 (34.6)
2005–2009 136 (14.7) 34 (12.5) 166 (14.6) 40 (5.7)
At least one diagnosis of long-term disease, n (%)
Severe hypertension 148 (16.0) 32 (11.8) 171 (15.0) 66 (9.4)
Cardiovascular diseases 139 (15.0) 45 (16.5) 173 (15.2) 93 (13.2)
Psychiatric disorders 59 (6.4) 14 (5.1) 62 (5.4) 27 (3.8)
Other diseases 202 (21.8) 63 (23.2) 247 (21.7) 125 (17.8)
Systemic drug dispensing, mean (SD)
A10, oral glucose-lowering 9.5 (5.8) 4.5 (4.9) 9.4 (5.9) 4.5 (5.2)
Other A, gastrointestinal tract/metabolism 3.4 (4.5) 2.8 (4.0) 3.3 (4.5) 2.9 (4.2)
B, blood and blood forming organs 2.8 (3.6) 2.2 (3.1) 2.9 (3.6) 2.7 (3.5)
C10, lipid-modifying agents 2.8 (3.0) 1.5 (2.4) 2.9 (3.0) 2.0 (2.8)
Other C, cardiovascular system 11.7 (10.1) 9.0 (8.8) 11.7 (10.0) 11.8 (10.0)
G, genito-urinary system 0.8 (2.0) 0.4 (1.3) 0.7 (2.0) 0.5 (1.7)
H, endocrine system 0.9 (2.1) 0.8 (1.8) 0.9 (2.1) 0.6 (1.7)
J07, vaccines 0.4 (0.5) 0.2 (0.5) 0.3 (0.5) 0.2 (0.4)
Other J, anti-infectives for systemic use 0.8 (1.3) 0.8 (1.4) 0.8 (1.3) 0.7 (1.3)
L, anti-neoplastic and immunomodulating agents 0.1 (0.5) 0.1 (0.5) 0.1 (0.6) 0.1 (0.5)
M, muscles, bones and joints 1.4 (2.7) 1.0 (2.1) 1.4 (2.7) 1.1 (2.3)
N01–N02, analgesics–anaesthetics 2.7 (3.3) 2.1 (2.4) 2.7 (3.3) 2.5 (2.9)
Other N, brain and nervous system 4.2 (6.7) 3.3 (5.6) 4.0 (6.4) 4.0 (6.1)
P, anti-parasitic products 0.0 (0.2) 0.0 (0.1) 0.0 (0.2) 0.0 (0.1)
R, respiratory system 1.7 (4.1) 1.3 (3.3) 1.6 (3.9) 1.5 (3.7)
S, sensory organs 1.0 (2.7) 0.7 (2.3) 1.1 (2.8) 1.1 (3.3)
PR
b, mean (SD)
Insulin 57.9 (23.4) 65.0 (24.8) 58.4 (22.9) 65.1 (23.2)
Biguanide 41.8 (41.2) 17.1 (32.6) 41.8 (40.8) 20.9 (35.3)
Sulfonylurea 36.8 (40.8) 15.3 (30.9) 35.7 (40.2) 17.4 (32.1)
Other oral glucose-lowering agents 26.8 (37.3) 8.4 (24.3) 26.9 (36.9) 10.7 (26.3)
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[7, 8, 11] compared with those exposed only to human
insulin. Our findings did not reproduce these results. On the
contrary, we can confidently rule out the possibility that the
i n c r e a s e dr i s kr e p o r t e di nt hose studies applied in our
population. In all population groups studied, the point
estimate of the HR for the risk of cancer with insulin glargine
was below one. Our results are consistent with some of the
experimental data [31]. Other studies have also found a
similar point estimate around 0.80 for the risk of cancer with
insulin glargine compared with human insulin [9, 29].
Similarly, we found no excess risk of breast cancer with
insulin glargine.
Among the previously published studies, Hemkens et al.
[7] reported an excess incidence of cancer only after adjust-
ing for dose of insulin glargine. We were not able to adjust
for dose, but did adjust for dispensing (PR) as a proxy for
exposure. In doing so, we found that there was an increased
risk of cancer with increased relative dispensing of insulin
and that this was common to all insulins tested by us, with
no interaction with the type of insulin. What might be
thought unusual is that Hemkens et al. did not find a dose-
Table 2 Hazard ratios from multivariate Cox proportional hazards models for diagnosis of cancer in patients with type 2 diabetes exposed to
insulin glargine or human insulin, stratified by propensity score quartiles users as indicated
Variable Incident users All users
Exclusive Predominant Exclusive Predominant
Number of patient-years exposure
Human insulin 614.2 820.5 1,705.4 2,341.0
Insulin glargine 2,272.8 2,800.3 2,342.1 3,125.1
Number of cases of cancer
Human insulin (n) 1 41 75 45 7
Insulin glargine (n) 4 14 44 24 6
Cancer incidence per 1,000 person-years, HR (95% CI)
Human insulin 22.8 (10.9, 34.7) 20.7 (10.9, 30.6) 31.7 (23.2, 40.1) 24.3 (18.0, 30.7)
Insulin glargine 18.0 (12.5, 23.6) 15.7 (11.1, 20.4) 17.9 (12.5, 23.4) 14.7 (10.5, 19.0)
Crude HR (95% CI)
Human insulin 1.0 1.0 1.0 1.0
Insulin glargine 0.80 (0.44, 1.47) 0.76 (0.43, 1.33) 0.53 (0.35, 0.80) 0.57 (0.39, 0.84)
Adjusted HR (95% CI)
Human insulin 1.0 1.0 1.0 1.0
Insulin glargine 0.59 (0.28, 1.25) 0.60 (0.31, 1.18) 0.61 (0.32, 1.18) 0.58 (0.34, 1.01)
New long-term disease
after initiation of insulin
1.08 (0.50, 2.33) 1.03 (0.50, 2.12) 0.66 (0.35, 1.25) 0.78 (0.43, 1.40)
IPR
0–39% 1.0 1.0 1.0 1.0
40–59% 1.12 (0.51, 2.48) 1.14 (0.53, 2.45) 1.03 (0.53, 2.00) 1.10 (0.58, 2.07)
60–79% 1.75 (0.82, 3.73) 1.63 (0.78, 3.38) 1.51 (0.82, 2.80) 1.47 (0.81, 2.68)
80–100% 2.14 (0.97, 4.72) 2.05 (0.95, 4.45) 2.33 (1.28, 4.22) 2.26 (1.26, 4.06)
Sulfonylureas PR
0–19% 1.0 1.0 1.0 1.0
20–79% 1.15 (0.52, 2.55) 1.03 (0.47, 2.24) 1.25 (0.71, 2.20) 1.25 (0.71, 2.20)
80–100% 2.30 (1.17, 4.54) 2.69 (1.42, 5.09) 1.98 (1.17, 3.35) 2.28 (1.38, 3.76)
Biguanides PR
0–19% 1.0 1.0 1.0 1.0
20–79% 0.51 (0.21, 1.21) 0.52 (0.23, 1.16) 0.48 (0.23, 1.00) 0.49 (0.24, 0.98)
80–100% 0.82 (0.43, 1.57) 0.74 (0.40, 1.38) 0.98 (0.60, 1.59) 0.92 (0.57, 1.48)
Other oral glucose-lowering agent PR
0–19% 1.0 1.0 1.0 1.0
20–79% 0.65 (0.26, 1.59) 0.82 (0.37, 1.81) 0.71 (0.35, 1.45) 0.77 (0.40, 1.47)
80–100% 1.04 (0.46, 2.34) 1.04 (0.46, 2.33) 1.08 (0.59, 1.98) 1.05 (0.57, 1.92)
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Jonasson et al. [8] reported an excess incidence of breast
cancer only, but not of all cancers or any other cancer.
Further analyses of the same population over different time
periods were unable to reproduce the increased risk found
initially [13]. The findings of the SDRN Epidemiology
Group were inconsistent across the different study designs,
with some (but not all) study designs suggesting an excess
of all cancer incidence and breast cancer [11]. We found no
such increase in any of our study populations. In fact, we
found a numerically lower rate of breast cancer in insulin
glargine users than in human insulin users.
The explanation of why our findings do not confirm
those of these previous studies might reside in possible
biases, either in previous studies, or in the present study.
We can probably exclude most biases concerning case
ascertainment or selection. In this reimbursement database,
randomly selected patients from the national healthcare
insurance databases are prospectively registered, and data
are collected prospectively and independently of patients,
prescribers or any pre-specified hypothesis. Our population
is by design representative of the French population [25].
Registration for long-term diseases is mandatory for patients
to receive full cover for healthcare expenditures related to
the disease. Thus it is very unlikely that patients treated for
cancer would not be registered to obtain full cover for this
expensive disease. There is no reason for diagnoses of cancer
to have been registered differently for patients treated with
insulin glargine compared with those on human insulin.
It also seems unlikely that human insulin was channelled
to higher cancer risk patients or insulin glargine to lower-
risk patients. The very small effect of the propensity score
stratification on the results indicates that there were very
small differences between the insulin user populations. Most
of our patients were included in the database before the
alerts on insulin glargine and cancer risk in 2009, which
was, in fact, the end of the inclusion period. Following the
notorious putative cancer risk alert for insulin glargine, any
change in indication or reduction in the use of insulin
glargine in patients suspected to be at higher risk of cancer
would have appeared only in 2009, and would therefore
have affected only a very small proportion of the patients.
Increased awareness of a possible risk of cancer with insulin
glargine might have increased detection of cancer in insulin
glargine users, but again this would only have happened at
the very end of the follow-up period. This potential detec-
tion bias might have explained a higher apparent risk of
cancer in insulin glargine users, but this is not what we
found. We adjusted for common confounders, such as age,
duration of exposure and concomitant diseases. The latter
include markers of increased risk of cancer, such as coro-
nary heart disease or peripheral arterial disease, but these,
too, were not less frequent in insulin glargine users than in
human insulin users. We were unable to adjust for BMI or
smoking, but there is no indication that these would be
confounders modifying prescription patterns and resulting
in a distorted apparent risk. BMI is associated with cancer
and with type 2 diabetes [32–36], although it is unclear
Table 3 Event rates per thousand patient-years of follow-up for the more common cancer types in incident exclusive users and in all predominant
users of insulin glargine or human insulin
Type of cancer Incident exclusive users All predominant users
Insulin glargine
a Human insulin
b Insulin glargine
c Human insulin
d
n Event rate, ‰ person-
years (95% CI)
n Event rate, ‰ person-
years (95% CI)
n Event rate, ‰ person-
years (95% CI)
n Event rate, ‰ person-
years (95% CI))
All cancers 41 18.0 (12.5, 23.6) 14 22.8 (10.9, 34.7) 46 14.7 (10.5, 19.0) 57 24.3 (18.0, 30.7)
Prostate
e 8 7.1 (3.1, 14.0) 2 6.4 (1.0, 30.3) 9 5.8 (2.7, 11.0) 11 11.7 (4.8, 18.7)
Lung 6 2.6 (1.0, 5.7) 1 1.6 (0.0, 0.1) 6 1.9 (0.7, 4.2) 5 2.1 (0.7, 5.0)
Pancreas 4 1.8 (0.5, 4.5) 3 4.9 (1.0, 14.3) 4 1.3 (0.3, 3.3) 5 2.1 (0.7, 5.0)
Breast
f 2 1.7 (0.2, 6.3) 3 8.0 (1.7, 23.4) 2 1.3 (0.2, 4.6) 8 5.7 (2.5, 11.2)
Colorectal 3 1.3 (0.3, 3.9) 1 1.6 (0.0, 9.1) 5 1.6 (0.5, 3.7) 6 2.6 (0.9, 5.6)
Bladder 2 0.9 (0.1, 3.2) 1 1.6 (0.0, 9.1) 3 1.0 (0.2, 2.8) 1 0.4 (0.0, 2.4)
Liver, biliary duct 2 0.9 (0.1, 3.2) 1 1.6 (0.0, 9.1) 2 0.6 (0.1, 2.3) 2 0.9 (0.1, 3.1)
an0927, 2,272.8 person-years;
bn0272, 614.2 person-years;
cn01,140, 3,125.1 person-years;
dn0703, 2,341.0 person-years
eIn incident exclusive users, men: insulin glargine 1,125.3 person-years, human insulin 239.0 person-years; in all predominant users, men: insulin
glargine 1,551.9 person-years, human insulin 936.5 person-years
fIn incident exclusive users, women: insulin glargine 1,147.3 person-years, human insulin 375.2 person-years; in all predominant users, women:
insulin glargine 1,573.1 person-years, human insulin 1,404.5 person-years
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resistance [37]. In other studies, there was no difference in
mean BMI between different insulin groups in type 2 dia-
betic patients, and there is no medical reason to prefer one
insulin over the other on the basis of BMI. We did not
account for smoking, but any confounding would result
from a preferential use of one or the other type of insulin
in smokers or non-smokers, which seems unlikely. In addi-
tion, there was no indication of a different rate of lung
cancer, or of diagnoses involving chronic lung disease or
other proxies such as coronary heart disease. On the other
hand, we confirmed the increased risk of cancer diagnoses
with increasing use of insulin (any type) or increasing use of
sulfonylureas in all population groups, a finding that supports
the notion that insulin as such plays a cancer-promoting role,
be it exogenously added or endogenously secreted upon stim-
ulation [38]. We did not confirm the protective effect of
biguanides [16], although the risk of cancer with biguanides
was indeed lower than in sulfonylurea users.
The first conclusion of our study is therefore that we
found no confirmation of the hypothesis that patients ex-
posed only to insulin glargine have a higher risk of cancer
(including breast cancer) than those exposed only to human
insulin. On the contrary, we found fewer cancer diagnoses in
insulin glargine than in human insulin users.
One explanation of our finding could be concurrent risk
bias. Thus if patients treated with insulin glargine died
sooner than patients on human insulin, they might be at less
apparent risk of developing cancer. However, we found the
opposite, namely that patients on insulin glargine tended to
die less soon than patients on human insulin, a finding that
in some cohorts reached significance. Again, the risk of
ascertainment bias would be low, since registration of death
comes from the census bureau and the pension funds, and is
independent of treatment or use of healthcare resources. We
have no indication as to whether the increased death rate is
due to the insulin chosen, or to patient selection or channel-
ling of human insulin to more severely ill patients than those
on insulin glargine. Different death rates between insulin
glargine and human insulin users have not been reported in
clinical trials of insulin glargine, but patients randomised to
insulin glargine had fewer episodes of hypoglycaemia, a
condition that might predispose to earlier death [39]. The
follow-up was short in the above trials. In actual practice,
human insulin might have been chosen for tighter control of
diabetes [40–42], which has also been associated with
higher mortality rates [43]. Higher all-cause death rates
might reduce the apparent risk of cancer in users of human
insulin and could perhaps help explain findings in other
epidemiological studies showing higher rates of cancer with
insulin glargine or lower rates with comparators. None of
the above studies reported on all-cause death or other com-
peting risks. One retrospective study comparing use of bolus
insulin analogues with bolus human insulin in hospital also
found that the death rate in patients treated with human
insulin was double that of patients given insulin analogues,
results that are quantitatively not very different from ours,
albeit in a very different setting [44].
Because our analysis of deaths was exploratory without
any pre-formulated hypothesis, the exact role of the patient
status or the choice of insulin remains to be determined. It
would, therefore, be desirable to re-analyse clinical trials
comparing analogues with human insulin for all-cause death
rates and to verify our findings in other settings and other
databases.
In conclusion, we did not confirm previous findings of an
increased risk of cancer with insulin glargine compared with
human insulin. We did, however, confirm the increased risk
of cancer with higher insulin or sulfonylurea exposure. We
also found an increased risk of all-cause death with human
insulin compared with insulin glargine, a finding that cer-
tainly warrants further exploration.
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